PASW

HONG KONG, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced that it has entered into a definitive purchase agreement (the “Agreement”) with Future Biotechnology Group Co., Limited for the acquisition (the “Acquisition”) of three tumor cell-related medical technology patents covering areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, for a consideration of US$2.3 million.

HONG KONG, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced its entry into a letter of intent with Future Biotechnology Group Co., Limited (the “Letter of Intent”), for the planned acquisition (the “Planned Acquisition”) of three tumor cell-related medical technology patents covering areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, for a consideration ranging from US 2 million to US 2.5 million.

HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (“Ping An Bio” or the “Company”) announced that its board of directors has approved a 1-for-40 reverse stock split of the Company's class A ordinary shares and class B ordinary shares.

HONG KONG, July 22, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (hereinafter referred to as “Ping An Biomedical”) announced that it has formally signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd.